Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
6 affiliations
- 1Department of Respiratory Medicine, Luzhou Maternal & Child Health Hospital, Luzhou Second People’s Hospital, Luzhou Women and Children’s Hospital, Luzhou, Sichuan, 646000, People’s Republic of China
- 2Department of Health Management Center, Luzhou Maternal & Child Health Hospital, Luzhou Second People’s Hospital, Luzhou Women and Children’s Hospital, Luzhou, Sichuan, 646000, People’s Republic of China
- 3School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, 610500, People’s Republic of China
- 4Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, 310003, People’s Republic of China
- 5Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China
- 6Wolfson Institute for Biomedical Research, UCL Division of Medicine, University College London, London, WC1E 6BT, UK
Abstract
Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route–Antigen–Microenvironment–Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.
Related
- Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
- Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine
- A Narrative Review of Nanomedicine in Cancer Therapy: Modulating Metabolic Reprogramming to Enhance Immunotherapy.
- Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy
- Mechanism-Driven Nanomedicine for Radiation Injury and Protection: Redox Homeostasis, the DNA Damage Response, and Microbiome-Based Strategies.
BibTeX
@article{he2026nanomedicineenhanced,
title = {{Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy}},
author = {Xianye He and Jiao He and Zhongsong Zhang and Yuanyin Teng and Bing Wang and Hao Sun and Xiang Deng and Junjun Xiong and Yuzhuo Huang},
journal = {International Journal of Nanomedicine},
year = {2026},
month = nov,
doi = {10.2147/ijn.s651751},
url = {https://doi.org/10.2147/ijn.s651751},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
AU - Xianye He
AU - Jiao He
AU - Zhongsong Zhang
AU - Yuanyin Teng
AU - Bing Wang
AU - Hao Sun
AU - Xiang Deng
AU - Junjun Xiong
AU - Yuzhuo Huang
PY - 2026
DA - 2026/11/08
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s651751
UR - https://doi.org/10.2147/ijn.s651751
AB - Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route–Antigen–Microenvironment–Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.
SN - 1176-9114
SN - 1178-2013
ER -